NEW YORK (GenomeWeb) – BG Medicine has entered in financing agreements for $2.5 million, the company disclosed in a document filed with the US Securities and Exchange Commission on Tuesday.

The firm entered into a securities purchase agreement with its principal shareholders Applied Genomic Technology Capital Fund, AGTC Advisors Fund, and Flagship Ventures Fund, under which BG Medicine sold secured convertible promissory notes totaling $500,000. 

Additionally, BG Medicine has agreed to sell to the purchasers $2 million of newly created Series A preferred stock. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.